cancer

2nd International Symposium on Frontiers in Molecular Science

Non-Coding RNAs & Epigenetics in Cancer

 

2nd International Symposium on Frontiers in Molecular Science Non-Coding RNAs and Epigenetics in Cancer logo

21–23 June 2017

Biocenter, University of Basel, Basel, Switzerland

Announcement: Final Deadline for Early Registration Fees 31 March 2017

An international scientific conference organized by the MDPI journals International Journal of Molecular Sciences and Non-Coding RNA

One of the most unexpected and fascinating discoveries in oncology over the past decade has been the interplay between abnormalities in protein-coding genes and non-coding RNAs (ncRNAs), which are causally involved in cancer initiation, progression, and dissemination. Although, to date, the most studied non-coding RNAs (ncRNAs) are miRNAs, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. At the conference, entitled “Non-Coding RNAs and Epigenetics in Cancer”, leaders in the field will present the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges. We hope to see you all, young in spirit and mind, in the new Eldorado of Science topics in biomedical sciences!

The Non-Coding RNAs and Epigenetics in Cancer will be held in Basel, Switzerland, from 21st to 23rd of June 2017. It will comprise five plenary sessions to highlight the most exciting developments and the latest breakthroughs in oncology.

If you are interested in participating in this conference, and in presenting a poster, or in being selected for a short talk, please register and get in touch with the conference secretariat. The program of the conference is being assembled and will be fully available by March 2017.

For more details and to register: http://sciforum.net/conference/ncRNA-Cancer

{ 0 comments }

New Nature Reviews Drug Discovery publication in the Series “RNA-based therapies”:

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Summary of the key steps in the development of miRNA therapeutics.Abstract: In just over two decades since the discovery of the first microRNA (miRNA), the field of miRNA biology has expanded considerably. Insights into the roles of miRNAs in development and disease, particularly in cancer, have made miRNAs attractive tools and targets for novel therapeutic approaches. Functional studies have confirmed that miRNA dysregulation is causal in many cases of cancer, with miRNAs acting as tumour suppressors or oncogenes (oncomiRs), and miRNA mimics and molecules targeted at miRNAs (antimiRs) have shown promise in preclinical development. Several miRNA-targeted therapeutics have reached clinical development, including a mimic of the tumour suppressor miRNA miR-34, which reached phase I clinical trials for treating cancer, and antimiRs targeted at miR-122, which reached phase II trials for treating hepatitis. In this article, we describe recent advances in our understanding of miRNAs in cancer and in other diseases and provide an overview of current miRNA therapeutics in the clinic. The authors also discuss the challenge of identifying the most efficacious therapeutic candidates and provide a perspective on achieving safe and targeted delivery of miRNA therapeutics.

Rupaimoole R, Slack FJ.
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017 Mar;16(3):203-222.
doi: 10.1038/nrd.2016.246. Review. PubMed PMID: 28209991.

Full article: http://www.nature.com/nrd/journal/v16/n3/full/nrd.2016.246.html

 

{ 0 comments }

starBase v2.0 logoStarBase has been updated to explore Pan-Cancer pattern of lncRNAs, miRNAs, RNA-binding proteins (RBP) and their regulatory networks (ceRNA, coexpression) by mining expression profiles of miRNAs, lncRNAs and mRNAs across 14 cancer types (>6000 samples) from The Cancer Genome Atlas (TCGA) Data Portal (all data available without limitations).
StarBase provides the following Pan-Cancer Analysis Services:
  1. starBase constructed Pan-Cancer expression profiles of lncRNAs, miRNAs from TCGA RNA-Seq and miRNA-Seq data.
  2. starBase generated Pan-Cancer networks of CLIP-Seq experimentally supported miRNA-lncRNA and miRNA-mRNA interactions.
  3. starBase identified Pan-Cancer ceRNA networks involving lncRNAs and mRNAs by analyzing >6000 tumor and normal samples and [click to continue…]

{ 0 comments }

Mirna Broadens Rights to Its Lead Cancer Therapeutic Candidate MRX34

Marina Biotech LogoBOSTON, MA and AUSTIN, TX–(Marketwired – Jan 2, 2014) – Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc. (Mirna), a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna’s proprietary microRNAs and Marina Biotech’s novel SMARTICLES liposomal delivery technology. Under terms of the amendment, Mirna paid certain pre-payments to Marina Biotech and now has additional rights to its lead program, MRX34, currently in Phase 1 clinical development for patients with unresectable primary liver cancer or metastatic cancer with liver involvement. In addition, under the terms of the license agreement, Mirna has optioned exclusivity on several additional miRNA targets. Further terms of the Agreement were not disclosed.

“Mirna and Marina Biotech have enjoyed a successful, durable collaboration by leveraging the systemic delivery of our proprietary, double-stranded, miRNA mimics with the SMARTICLES delivery technology,” said Paul Lammers, President and CEO of Mirna Therapeutics. “Amendment of the license agreement strengthens [click to continue…]

{ 0 comments }

Expands the Company’s Patent Portfolio in Oncology Therapeutics

Rosetta Genomics LogoPRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Nov 7, 2013) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled “Targeting microRNAs for the Treatment of Liver Cancer.”

This allowance is for a therapeutic patent that protects a method for treating hepatocellular carcinoma (HCC), or liver cancer, and covers the administration of a compound comprising a modified oligonucleotide that is an anti-miR-222. In addition, various modifications of the nucleotide are claimed. There is an additional claim which refers to the reduction of the levels of serum alpha-fetoprotein or serum des-gamma-carboxyprothrombin in the subject to be treated.

“HCC is the fifth most common cancer in the world and the third leading cause of cancer deaths. Because standard chemotherapy usually has no beneficial outcome on HCC patients, there is significant need for new therapeutic modalities and novel therapeutic [click to continue…]

{ 0 comments }

Rosetta Genomics Reports Financial Results for the First Six Months of 2013

September 10, 2013

Demonstrating Increased Demand for the Rosetta Cancer Origin Test PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Sep 10, 2013) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reports financial results for the six months ended June 30, 2013. Commercial highlights for the first half of 2013 and recent weeks include: Enhanced […]

Read the full article →

miRNAs and Bladder Cancer – Study Validating Ability of microRNAs to Predict Progression

February 7, 2013

NOTE: hsa-miR-29c* mentioned in the following paper is the retired name for what is now hsa-miR-29c-5p: http://www.mirbase.org/cgi-bin/mature.pl?mature_acc=MIMAT0004673 PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as […]

Read the full article →

Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors

January 9, 2013

PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published […]

Read the full article →

Rosetta Genomics and Precision Therapeutics Announce U.S. Commercial Launch of miRview® mets2

October 2, 2012

Medicare-Covered Assay Accurately Identifies Tumor of Origin in Cancer of Unknown Primary PHILADELPHIA, REHOVOT, Israel, and PITTSBURGH, Oct. 2, 2012 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, and Precision Therapeutics, Inc. (PTI), a life science company known for its expertise in the science of personalizing cancer […]

Read the full article →

miREC: Database of miRNAs involved in endometrial cancer

September 19, 2012

The miREC database (miRNAs involved in Endometrial Cancer) combines published data about miRNAs and genes deregulated in endometrial cancer, as well as target-regulator relationships between these genes and miRNAs. All information has been extracted from published literature and entries are supplemented by reference citations. The miREC database was launched in February 2011  by researchers at […]

Read the full article →